



11

14

15

17

18

22

24

26

28

30

31

33

Article

# Determining risk of diabetes and cardiovascular diseases occurrence utilizing data via smart devices

Firstname Lastname <sup>1,†,‡</sup>, Firstname Lastname <sup>2,‡</sup> and Firstname Lastname <sup>2,\*</sup>

- <sup>1</sup> Affiliation 1; e-mail@e-mail.com
- <sup>2</sup> Affiliation 2; e-mail@e-mail.com
- Correspondence: e-mail@e-mail.com; Tel.: (optional; include country code; if there are multiple corresponding authors, add author initials) +xx-xxxx-xxxx (F.L.)
- † Current address: Affiliation 3.
- ‡ These authors contributed equally to this work.

Abstract: A single paragraph of about 200 words maximum. For research articles, abstracts should give a pertinent overview of the work. We strongly encourage authors to use the following style of structured abstracts, but without headings: (1) Background: place the question addressed in a broad context and highlight the purpose of the study; (2) Methods: describe briefly the main methods or treatments applied; (3) Results: summarize the article's main findings; (4) Conclusions: indicate the main conclusions or interpretations. The abstract should be an objective representation of the article, it must not contain results which are not presented and substantiated in the main text and should not exaggerate the main conclusions.

**Keywords:** keyword 1; keyword 2; keyword 3 (List three to ten pertinent keywords specific to the article; yet reasonably common within the subject discipline.)

## 0. How to Use this Template

The template details the sections that can be used in a manuscript. Note that the order and names of article sections may differ from the requirements of the journal (e.g., the positioning of the Materials and Methods section). Please check the instructions on the authors' page of the journal to verify the correct order and names. For any questions, please contact the editorial office of the journal or support@mdpi.com. For LaTeX-related questions please contact latex@mdpi.com.

#### 1. Introduction

The introduction should [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16] briefly place the study in a broad context and highlight why it is important. It should define the purpose of the work and its significance. The current state of the research field should be reviewed carefully and key publications cited. Please highlight controversial and diverging hypotheses when necessary. Finally, briefly mention the main aim of the work and highlight the principal conclusions. As far as possible, please keep the introduction comprehensible to scientists outside your particular field of research. Citing a journal paper. Now citing a book reference or other reference types. Please use the command for the following MDPI journals, which use author–date citation: Administrative Sciences, Arts, Econometrics, Economies, Genealogy, Humanities, IJFS, Journal of Intelligence, Journalism and Media, JRFM, Languages, Laws, Religions, Risks, Social Sciences, Literature.

### 2. Related Work

As mentioned before, the applications of Statistical Analysis and Machine Learning in healthcare and more specifically in diabetes condition have demonstrated a steady rise in the last two decades, since the development of corresponding programming frameworks have enabled the easy storage, collection, processing, analysis of the massively

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. *Journal Not Specified* 2022, 1, 0. https://doi.org/

Received: Accepted:

Published:

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Submitted to *Journal Not Specified* for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

38

40

42

49

51

5 5

59

61

62

70

72

79

80

81

85

available data quantity and employment of statistical and Machine Learning models [17–19]. Regarding diabetes research field, the literature deals with the identification of diabetic people, early or long term (2-10 years) prognosis and diabetes complications prediction or identification.

Our literature review is focused on relatively new research articles or systematic reviews which are related with the context of our article e.g prediction of diabetes mellitus or prediabetes utilizing demographic, anthropometric, biometric, laboratory, nutritional, medical history, etc. data as input features. The first mathematical approaches over diabetes issue consisted of statistical risk scores exploiting questionnaires filled by waves from the participants. Some of the famous ones risk scores are Leicester Risk Assessment Score[20] developed by Leicester University and FINDRISC [21] developed by University of Helsinki. The former utilizing a Logistic Regression model, take into account age, ethnicity, sex, first degree family history of diabetes, antihypertensive therapy or history of hypertension, waist circumference and BMI to predict current impaired glucose regulation or diabetes mellitus, achieving an AUC metric of 72% and the latter -also exploited Logistic Regressionuses gender, age, BMI, use of blood pressure medication, history of high blood glucose, physical activity, daily consumption of vegetables, fruits or berries and family history of diabetes to predict a 10-year development achieving an AUC metric of 86%. We can observe at a first glance two variances of diabetes studies. The Leicster Risk aims to identify the current health condition, while FINDRISC tries to predict a long term prevalence. There are also numerous researches that deal with deep learning and more specifically with image recognition for the classification of diabetic retinopathy, which is a typical complication and very well studied in the research field, using images from eye bulb as input [2,12]. Another diabetes complications studies utilizing Machine Learning and Deep Learning include neuropathy and nephropathy [2,12]. Apart from classification problems there are also regression methods which are exploited for the prediction of Fasting Plasma Glycose or HbA1c levels, i.e. biomarkers that are the best indicators of abnormal glycose regulation and consequently diabetes mellitus presence [2,3,12].

Delving more into literature that is more relevant with the purpose of this study we can observe an adequate quantity of high quality articles which will help to understand a principal methodology in order to identify or predict diabetes development. Next, the chosen papers will be clustered based on their purpose, their key methodologies will be in a more detailed context described and also each other compared for advantages and disadvantages.

The detection of diabetes is studied in [4]. The dataset used is PIMA from UCI repository [22]. First, during the feature selection procedure, methods like information gain, gain ratio, gini index, ANOVA,  $\chi^2$  test, an extension of Relief, correlation, fast correlation and filter subset evaluation where employed. Glucose levels, BMI, diabetes pedigree function and age was identified as the best features on average from the aforementioned techniques. Then, a variety of models was trained and tested on the different feature subsets derived from the feature selection techniques using 10 fold cross validation. The models probed were GAMBoost, regularized logistic regression, penalized multinomial regression, Bayesian generalized linear model, penalized logistic regression, generalized linear model, sparse distance weighted discrimination, generalized boosted regression model and Naive Bayes. Generalized additive using LOESS yeld the best AUC 85.36% and achieved Sensitivity, Specificity 86%, 60%.

#### 3. Materials and Methods

Materials and Methods should be described with sufficient details to allow others to replicate and build on published results. Please note that publication of your manuscript implicates that you must make all materials, data, computer code, and protocols associated with the publication available to readers. Please disclose at the submission stage any restrictions on the availability of materials or information. New methods and protocols

92

97

101

102

103

104

106

108

109

110

112

should be described in detail while well-established methods can be briefly described and appropriately cited.

Research manuscripts reporting large datasets that are deposited in a publicly available database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

Interventionary studies involving animals or humans, and other studies require ethical approval must list the authority that provided approval and the corresponding ethical approval code.

This is an example of a quote.

4. Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

4.1. Subsection
4.1.1. Subsubsection

Bulleted lists look like this:

First bullet;Second bullet;

Third bullet.
 Numbered lists can be added as follows:

First item;
 Second item;

2. Second item;3. Third item.

The text continues here.

4.2. Figures, Tables and Schemes

All figures and tables should be cited in the main text as Figure 1, Table 1, Table 2, etc. 114



**Figure 1.** This is a figure. Schemes follow the same formatting. If there are multiple panels, they should be listed as: (a) Description of what is contained in the first panel. (b) Description of what is contained in the second panel. Figures should be placed in the main text near to the first time they are cited. A caption on a single line should be centered.

120

121

**Table 1.** This is a table caption. Tables should be placed in the main text near to the first time they are cited.

Title 1	Title 2	Title 3
Entry 1	Data	Data
Entry 2	Data	Data

**Table 2.** This is a wide table.

Title 1	Title 2	Title 3	Title 4
Entry 1	Data	Data	Data
Entry 2	Data	Data	Data <sup>1</sup>

<sup>&</sup>lt;sup>1</sup> This is a table footnote.

Text. 115

4.3. Formatting of Mathematical Components

This is the example 1 of equation:

$$a = 1, (1)$$

the text following an equation need not be a new paragraph. Please punctuate equations as regular text.

This is the example 2 of equation:

$$a = b + c + d + e + f + g + h + i + j + k + l + m + n + o + p + q + r + s + t + u + v + w + x + y + z$$
 (2)



**Figure 2.** This is a wide figure.

Please punctuate equations as regular text. Theorem-type environments (including propositions, lemmas, corollaries etc.) can be formatted as follows:

**Theorem 1.** *Example text of a theorem.* 

122

132

135

138

140

146

147

156

162

166

167

168

171

173

174

The text continues here. Proofs must be formatted as follows:

**Proof of Theorem 1.** Text of the proof. Note that the phrase "of Theorem 1" is optional if it is clear which theorem is being referred to.  $\Box$ 

The text continues here.

5. Discussion

Authors should discuss the results and how they can be interpreted from the perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible. Future research directions may also be highlighted.

6. Conclusions

This section is not mandatory, but can be added to the manuscript if the discussion is unusually long or complex.

7. Patents

This section is not mandatory, but may be added if there are patents resulting from the work reported in this manuscript.

**Author Contributions:** For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used "Conceptualization, X.X. and Y.Y.; methodology, X.X.; software, X.X.; validation, X.X., Y.Y. and Z.Z.; formal analysis, X.X.; investigation, X.X.; resources, X.X.; data curation, X.X.; writing—original draft preparation, X.X.; writing—review and editing, X.X.; visualization, X.X.; supervision, X.X.; project administration, X.X.; funding acquisition, Y.Y. All authors have read and agreed to the published version of the manuscript.", please turn to the CRediT taxonomy for the term explanation. Authorship must be limited to those who have contributed substantially to the work reported.

**Funding:** Please add: "This research received no external funding" or "This research was funded by NAME OF FUNDER grant number XXX." and and "The APC was funded by XXX". Check carefully that the details given are accurate and use the standard spelling of funding agency names at <a href="https://search.crossref.org/funding">https://search.crossref.org/funding</a>, any errors may affect your future funding.

**Institutional Review Board Statement:** In this section, you should add the Institutional Review Board Statement and approval number, if relevant to your study. You might choose to exclude this statement if the study did not require ethical approval. Please note that the Editorial Office might ask you for further information. Please add "The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval)." for studies involving humans. OR "The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval)." for studies involving animals. OR "Ethical review and approval were waived for this study due to REASON (please provide a detailed justification)." OR "Not applicable" for studies not involving humans or animals.

**Informed Consent Statement:** Any research article describing a study involving humans should contain this statement. Please add "Informed consent was obtained from all subjects involved in the study." OR "Patient consent was waived due to REASON (please provide a detailed justification)." OR "Not applicable" for studies not involving humans. You might also choose to exclude this statement if the study did not involve humans.

Written informed consent for publication must be obtained from participating patients who can be identified (including by the patients themselves). Please state "Written informed consent has been obtained from the patient(s) to publish this paper" if applicable.

**Data Availability Statement:** In this section, please provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study. Please refer to suggested Data Availability Statements in section "MDPI Research Data Policies" at <a href="https://www.mdpi.com/ethics">https://www.mdpi.com/ethics</a>. If the study did not report any data, you might add "Not applicable" here.

178

182

183

192

196

198

199

200

201

202

203

204

207

209

210

212

213

214

215

**Acknowledgments:** In this section you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest: Declare conflicts of interest or state "The authors declare no conflict of interest." Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. If there is no role, please state "The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results".

Sample Availability: Samples of the compounds ... are available from the authors.

Abbreviations

The following abbreviations are used in this manuscript:

MDPI Multidisciplinary Digital Publishing Institute

DOAJ Directory of open access journals

TLA Three letter acronym LD Linear dichroism

Appendix A

Appendix A.1

The appendix is an optional section that can contain details and data supplemental to the main text—for example, explanations of experimental details that would disrupt the flow of the main text but nonetheless remain crucial to understanding and reproducing the research shown; figures of replicates for experiments of which representative data are shown in the main text can be added here if brief, or as Supplementary Data. Mathematical proofs of results not central to the paper can be added as an appendix.

**Table A1.** This is a table caption.

Title 1	Title 2	Title 3
Entry 1	Data	Data
Entry 2	Data	Data

Appendix B

All appendix sections must be cited in the main text. In the appendices, Figures, Tables, etc. should be labeled, starting with "A"—e.g., Figure A1, Figure A2, etc.

#### References

- Lama, L.; Wilhelmsson, O.; Norlander, E.; Gustafsson, L.; Lager, A.; Tynelius, P.; Wärvik, L.; Östenson, C.G. Machine learning for prediction of diabetes risk in middle-aged Swedish people. *Heliyon* **2021**, *7*, e07419. https://doi.org/https://doi.org/10.1016/j. heliyon.2021.e07419.
- 2. Kavakiotis, I.; Tsave, O.; Salifoglou, A.; Maglaveras, N.; Vlahavas, I.; Chouvarda, I. Machine Learning and Data Mining Methods in Diabetes Research. *Computational and Structural Biotechnology Journal* **2017**, *15*, 104–116. https://doi.org/10.1016/j.csbj.2016.12.005.
- 3. Kopitar, L.; Kocbek, P.; Cilar, L.; Sheikh, A.; Stiglic, G. Early detection of type 2 diabetes mellitus using machine learning-based prediction models. *Scientific reports* **2020**, *10*, 1–12.
- 4. Howlader, K.; Satu, M.; Awal, M.; Islam, M.; Shariful Islam, S.M.; Quinn, J.; Moni, M.A. Machine learning models for classification and identification of significant attributes to detect type 2 diabetes. *Health Information Science and Systems* **2022**, *10*. https://doi.org/10.1007/s13755-021-00168-2.
- 5. Deberneh, H.M.; Kim, I. Prediction of Type 2 Diabetes Based on Machine Learning Algorithm. *International Journal of Environmental Research and Public Health* **2021**, *18*. https://doi.org/10.3390/ijerph18063317.

221

222

223

224

228

229

230

231

232

233

234

235

240

242

243

250

251

252

253

- 6. Lai, H.; Huang, H.; Keshavjee, K.; Guergachi, A.; Gao, X. Predictive models for diabetes mellitus using machine learning techniques. *BMC Endocrine Disorders* **2019**, 19. https://doi.org/10.1186/s12902-019-0436-6.
- 7. Fazakis, N.; Kocsis, O.; Dritsas, E.; Alexiou, S.; Fakotakis, N.; Moustakas, K. Machine Learning Tools for Long-Term Type 2 Diabetes Risk Prediction. *IEEE Access* **2021**, *9*, 103737–103757. https://doi.org/10.1109/ACCESS.2021.3098691.
- 8. Zou, Q.; Qu, K.; Luo, Y.; Yin, D.; Ju, Y.; Tang, H. Predicting Diabetes Mellitus With Machine Learning Techniques. *Frontiers in Genetics* **2018**, 9. https://doi.org/10.3389/fgene.2018.00515.
- 9. De Silva, K.; Lim, S.; Mousa, A.; Teede, H.; Forbes, A.; Demmer, R.T.; Jönsson, D.; Enticott, J. Nutritional markers of undiagnosed type 2 diabetes in adults: Findings of a machine learning analysis with external validation and benchmarking. *PLOS ONE* **2021**, 16, 1–21. https://doi.org/10.1371/journal.pone.0250832.
- 10. Dinh, A.; Miertschin, S.; Young, A.; Mohanty, S. A data-driven approach to predicting diabetes and cardiovascular disease with machine learning. *BMC Medical Informatics and Decision Making* **2019**, *19*. https://doi.org/10.1186/s12911-019-0918-5.
- 11. Zhang, L.; Wang, Y.; Niu, M.; Wang, C.; Wang, Z. Machine learning for characterizing risk of type 2 diabetes mellitus in a rural Chinese population: the Henan Rural Cohort Study. *Scientific Reports* **2020**, *10*. https://doi.org/10.1038/s41598-020-61123-x.
- 12. Fregoso-Aparicio, L.; Noguez, J.; Montesinos, L.; García-García, J. Machine learning and deep learning predictive models for type 2 diabetes: a systematic review. *Diabetology & Metabolic Syndrome* **2021**, *13*. https://doi.org/10.1186/s13098-021-00767-9.
- 13. Xiong, X.I.; Zhang, R.; Bi, Y.; Zhou, W.h.; Yu, Y.; Zhu, D.I. Machine Learning Models in Type 2 Diabetes Risk Prediction: Results from a Cross-sectional Retrospective Study in Chinese Adults. *Current Medical Science* **2019**, *39*, 582–588. https://doi.org/10.1007/s11596-019-2077-4.
- 14. Rufo, D.D.; Debelee, T.G.; Ibenthal, A.; Negera, W.G. Diagnosis of Diabetes Mellitus Using Gradient Boosting Machine (LightGBM). *Diagnostics* **2021**, *11*. https://doi.org/10.3390/diagnostics11091714.
- 15. Morgan-Benita, J.A.; Galván-Tejada, C.E.; Cruz, M.; Galván-Tejada, J.I.; Gamboa-Rosales, H.; Arceo-Olague, J.G.; Luna-García, H.; Celaya-Padilla, J.M. Hard Voting Ensemble Approach for the Detection of Type 2 Diabetes in Mexican Population with Non-Glucose Related Features. *Healthcare* 2022, 10. https://doi.org/10.3390/healthcare10081362.
- 16. Dritsas, E.; Trigka, M. Data-Driven Machine-Learning Methods for Diabetes Risk Prediction. *Sensors* **2022**, 22. https://doi.org/10.3390/s22145304.
- 17. Frank, E.; Hall, M.A.; Holmes, G.; Kirkby, R.; Pfahringer, B.; Witten, I.H., Weka: A machine learning workbench for data mining. In *Data Mining and Knowledge Discovery Handbook: A Complete Guide for Practitioners and Researchers*; Maimon, O.; Rokach, L., Eds.; Springer: Berlin, 2005; pp. 1305–1314.
- 18. Pedregosa, F.; Varoquaux, G.; Gramfort, A.; Michel, V.; Thirion, B.; Grisel, O.; Blondel, M.; Prettenhofer, P.; Weiss, R.; Dubourg, V.; et al. Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* **2011**, *12*, 2825–2830.
- 19. Seabold, S.; Perktold, J. statsmodels: Econometric and statistical modeling with python. In Proceedings of the 9th Python in Science Conference, 2010.
- 20. Gray, L.J.; Taub, N.A.; Khunti, K.; Gardiner, E.; Hiles, S.; Webb, D.R.; Srinivasan, B.T.; Davies, M.J. The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. *Diabetic Medicine* 2010, 27, 887–895, [https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-5491.2010.03037.x]. https://doi.org/https://doi.org/10.1111/j.1464-5491.2010.03037.x.
- 21. Lindstrom, J.; Tuomilehto, J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. *Diabetes Care* **2003**, *26*, 725–731, [https://diabetesjournals.org/care/article-pdf/26/3/725/665299/dc0303000725.pdf]. https://doi.org/10.2337/diacare.26.3.725.
- 22. Dua, D.; Graff, C. UCI Machine Learning Repository, 2017.